Osteoclasts in RA: Diverse origins and functions

Joint Bone Spine

Volumn 80, Issue 6, 2013, Pages 586-591

  Le Goff, Benoit ^a,b,c,d   Berthelot, Jean Marie ^a,c   Maugars, Yves ^a,b,c,d   Heymann, Dominique ^a,b,c,d,e  

^a HÔTEL DIEU   (France)

^b LUNAM Universite   (France)

^c Universite de Nantes   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e Equipe Labellisee LIGUE 2012   (France)

Author keywords

B lymphocyte; Immune complexes; Osteoclasts; Rheumatoid arthritis; T lymphocyte; Toll like receptors

Indexed keywords

ABATACEPT; DENOSUMAB; PLACEBO; RITUXIMAB; TOCILIZUMAB; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; ZOLEDRONIC ACID;

ANTIGEN ANTIBODY COMPLEX; BONE EROSION; BONE TURNOVER; CELL FUNCTION; DRUG EFFECT; HEMATOPOIETIC CELL; HUMAN; MACROPHAGE ACTIVATION; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; REVIEW; RHEUMATOID ARTHRITIS; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ARTHRITIS, RHEUMATOID; BONE RESORPTION; HUMANS; OSTEOCLASTS;

EID: 84888430101     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2013.04.002     Document Type: Short Survey

References (64)

1. Karsdal M.A., Martin T.J., Bollerslev J., et al. Are nonresorbing osteoclasts sources of bone anabolic activity?. J Bone Miner Res 2007, 22:487-494.
2. Mansour A., Wakkach A., Blin-Wakkach C. Role of osteoclasts in the hematopoietic stem cell niche formation. Cell Cycle 2012, 11:2045-2046.
3. Mansour A., Abou-Ezzi G., Sitnicka E., et al. Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow. J Exp Med 2012, 209:537-549.
4. Yao Z., Xing L., Qin C., et al. Osteoclast precursor interaction with bone matrix induces osteoclast formation directly by an interleukin-1-mediated autocrine mechanism. J Biol Chem 2008, 283:9917-9924.
5. Mulherin D., Fitzgerald O., Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol 1996, 35:1263-1268.
6. Durand M., Boire G., Komarova S.V., et al. The increased in vitro osteoclastogenesis in patients with rheumatoid arthritis is due to increased percentage of precursors and decreased apoptosis: the In Vitro Osteoclast Differentiation in Arthritis (IODA) study. Bone 2011, 48:588-596.
7. Hirayama T., Danks L., Sabokbar A., et al. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis. Rheumatology (Oxford) 2002, 41:1232-1239.
8. Codriansky K.A., Runger T.M., Bhawan J., et al. Multicentric reticulohistiocytosis: a systemic osteoclastic disease?. Arthritis Rheum 2008, 59:444-448.
9. Gravallese E.M., Harada Y., Wang J.T., et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998, 152:943-951.
10. Fujikawa Y., Sabokbar A., Neale S., et al. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. Ann Rheum Dis 1996, 55:816-822.
11. Schett G., Firestein G.S. Mr Outside and Mr Inside: classic and alternative views on the pathogenesis of rheumatoid arthritis. Ann Rheum Dis 2010, 69:787-789.
12. Dalbeth N., Smith T., Gray S., et al. Cellular characterisation of magnetic resonance imaging bone oedema in rheumatoid arthritis; implications for pathogenesis of erosive disease. Ann Rheum Dis 2009, 68:279-282.
13. McQueen F.M., Benton N., Perry D., et al. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 2003, 48:1814-1827.
14. Lutzky V., Hannawi S., Thomas R. Cells of the synovium in rheumatoid arthritis. Dendritic cells. Arthritis Res Ther 2007, 9:219.
15. Rivollier A., Mazzorana M., Tebib J., et al. Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 2004, 104:4029-4037.
16. Wakkach A., Mansour A., Dacquin R., et al. Bone marrow microenvironment controls the in vivo differentiation of murine dendritic cells into osteoclasts. Blood 2008, 112:5074-5083.
17. Abou-Ezzi G. Osteoclasts modulate the balance between immunosuppression and inflammation through antigen presentation and interactions with CD4+ T cells. J Transl Med 2011, 9:56.
18. Pugliese L.S., Goncalves T.O., Popi A.F., et al. B-1 lymphocytes differentiate into functional osteoclast-like cells. Immunobiology 2012, 217:336-344.
19. Perez-Amodio S., Jansen D.C., Schoenmaker T., et al. Calvarial osteoclasts express a higher level of tartrate-resistant acid phosphatase than long bone osteoclasts and activation does not depend on cathepsin K or L activity. Calcif Tissue Int 2006, 79:245-254.
20. Shorey S., Heersche J.N., Manolson M.F. The relative contribution of cysteine proteinases and matrix metalloproteinases to the resorption process in osteoclasts derived from long bone and scapula. Bone 2004, 35:909-917.
21. Chappard D., Petitjean M., Alexandre C., et al. Cortical osteoclasts are less sensitive to etidronate than trabecular osteoclasts. J Bone Miner Res 1991, 6:673-680.
22. Niida S., Kaku M., Amano H., et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 1999, 190:293-298.
23. Lean J.M., Fuller K., Chambers T.J. FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. Blood 2001, 98:2707-2713.
24. Rifas L., Weitzmann M.N. A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. Arthritis Rheum 2009, 60:3324-3335.
25. Boissier M.C., Semerano L., Challal S., et al. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun 2012, 39:222-228.
26. Kwan Tat S., Padrines M., Theoleyre S., et al. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004, 15:49-60.
27. Mathsson L., Lampa J., Mullazehi M., et al. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells. Arthritis Res Ther 2006, 8:R64.
28. MacLellan L.M., Montgomery J., Sugiyama F., et al. Co-opting endogenous immunoglobulin for the regulation of inflammation and osteoclastogenesis in humans and mice. Arthritis Rheum 2012, 63:3897-3907.
29. Pierce A.M., Lindskog S. Evidence for capping of Fc gamma receptors on osteoclasts. Calcif Tissue Int 1986, 39:109-116.
30. van Lent P.L., Grevers L., Lubberts E., et al. Fcgamma receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: uncoupling of cartilage damage from bone erosion and joint inflammation. Arthritis Rheum 2006, 54:3868-3877.
31. Grevers L.C., de Vries T.J., Everts V., et al. Immune complex-induced inhibition of osteoclastogenesis is mediated via activating but not inhibitory Fcgamma receptors on myeloid precursor cells. Ann Rheum Dis 2013, 72:278-285.
32. Laurent L., Clavel C., Lemaire O., et al. Fcgamma receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins. Ann Rheum Dis 2011, 70:1052-1059.
33. Harre U., Georgess D., Bang H., et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012, 122:1791-1802.
34. Takami M., Kim N., Rho J., et al. Stimulation by toll-like receptors inhibits osteoclast differentiation. J Immunol 2002, 169:1516-1523.
35. Bar-Shavit Z. Taking a toll on the bones: regulation of bone metabolism by innate immune regulators. Autoimmunity 2008, 41:195-203.
36. Ji J.D., Park-Min K.H., Shen Z., et al. Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-gamma in human osteoclast precursors. J Immunol 2009, 183:7223-7233.
37. Wu H., Arron J.R. TRAF-6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology. Bioessays 2003, 25:1096-1105.
38. Umezu A., Kaneko N., Toyama Y., et al. Appearance of osteoclasts by injections of lipopolysaccharides in rat periodontal tissue. J Periodontal Res 1989, 24:378-383.
39. Pascaretti-Grizon F., Mabilleau G., Basle M.F., et al. Measurement by vertical scanning profilometry of resorption volume and lacunae depth caused by osteoclasts on dentine slices. J Microsc 2011, 241:147-152.
40. Pollinger B., Junt T., Metzler B., et al. Th17 cells, not IL-17+ gammadelta T cells, drive arthritic bone destruction in mice and humans. J Immunol 2011, 186:2602-2612.
41. Duvallet E., Semerano L., Assier E., et al. Interleukin-23: a key cytokine in inflammatory diseases. Ann Med 2011, 43:503-511.
42. Li H., Hong S., Qian J., et al. Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood 2010, 116:210-217.
43. Kiesel J., Miller C., Abu-Amer Y., et al. Systems level analysis of osteoclastogenesis reveals intrinsic and extrinsic regulatory interactions. Dev Dyn 2007, 236:2181-2197.
44. Kiesel J.R., Buchwald Z.S., Aurora R. Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells. J Immunol 2009, 182:5477-5487.
45. Buchwald Z.S., Kiesel J.R., DiPaolo R., et al. Osteoclast activated FoxP3+ CD8+ T cells suppress bone resorption in vitro. PLoS One 2012, 7:e38199.
46. Harre U., Keppeler H., Ipseiz N., et al. Moonlighting osteoclasts as undertakers of apoptotic cells. Autoimmunity 2012, 45:612-619.
47. Berthelot J.M., Le Goff B. Rheumatoid arthritis and periodontal disease. Joint Bone Spine 2010, 77:537-541.
48. Yeo L., Toellner K.M., Salmon M., et al. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis 2011, 70:2022-2028.
49. Sezer O. Myeloma bone disease. Hematology 2005, 10:19-24.
50. Bugatti S., Caporali R., Manzo A., et al. Involvement of subchondral bone marrow in rheumatoid arthritis: lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment. Arthritis Rheum 2005, 52:3448-3459.
51. Vaideeswar P., George S.M., Kane S.V., et al. Extranodal follicular dendritic cell sarcoma of the tonsil: case report of an epithelioid cell variant with osteoclastic giant cells. Pathol Res Pract 2009, 205:149-153.
52. Silvestris F., Ciavarella S., Strippoli S., et al. Cell fusion and hyperactive osteoclastogenesis in multiple myeloma. Adv Exp Med Biol 2011, 714:113-128.
53. Lipsky P.E., van der Heijde D.M., Saint-Clair E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343:1594-1602.
54. Smolen J.S., Avila J.C., Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis 2012, 71:687-693.
55. Axmann R., Bohm C., Kronke G., et al. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 2009, 60:2747-2756.
56. Axmann R., Herman S., Zaiss M., et al. CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 2008, 67:1603-1609.
57. Boumans M.J., Thurlings R.M., Yeo L., et al. Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Ann Rheum Dis 2012, 71:108-113.
58. Romas E. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates. Best Pract Res Clin Rheumatol 2005, 19:1065-1079.
59. Le Goff B., Berthelot J.M., Maugars Y., et al. Alternative use of bisphosphonate therapy for rheumatic disease. Curr Pharm Des 2010, 16:3045-3052.
60. Le Goff B., Soltner E., Charrier C., et al. A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen-induced arthritis. Arthritis Res Ther 2009, 11:R185.
61. Jarrett S.J., Conaghan P.G., Sloan V.S., et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 2006, 54:1410-1414.
62. McQueen F., Lloyd R., Doyle A., et al. Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study. Ann Rheum Dis 2011, 70:1091-1094.
63. Cohen S.B., Dore R.K., Lane N.E., et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008, 58:1299-1309.
64. Deodhar A., Dore R.K., Mandel D., et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res 2010, 62:569-574.